2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
1
Rare Diseases
across 2 areas
0
News (30d)
Quiet
Pharos iBio Co., Ltd. is a company with 2 orphan drug designations across 1 rare disease.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| acute myeloid leukemia | N-(4-methyl-3-(7-methyl-2-((6-methylpyridin-3-yl)amino)-8-oxo-7,8-dihydropyrido[3,4-d]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamideN-{2-[N-((3S)(3-piperidyl))carbamoyl]-5-[2-(3-fluorophenyl)ethynyl](3-thienyl)}aminoamide | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio